CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2011	Dec. 31, 2010
Current assets
Cash	$ 952,252	$ 238,565
Grants receivable		244,479
Prepaid drug product for testing	153,000	88,400
Other current assets	48,439	72,993
Total current assets	1,153,691	644,437
Other assets
Technology licenses - related party	2,868,877	3,043,821
Less Accumulated Amortization	(791,463)	(579,754)
Intangible Assets, Net (Excluding Goodwill), Total	2,077,414	2,464,067
TOTAL ASSETS	3,231,105	3,108,504
Current liabilities
Accounts payable	121,540	88,400
Accounts payable - related party	67,971
Accrued expense	46,082	67,841
Accrued expense - related party	41,000	16,300
Accrued license payments - related party	39,538	74,217
Total current liabilities	316,131	246,758
Long term debt
TOTAL LIABILITIES	316,131	246,758
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding
Common Stock, $.001 par value, 200,000,000 shares authorized 58,325,169 and 49,400,605 shares issued and outstanding as of 12/31/11 and 12/31/10, respectively	58,325	49,401
Additional paid in capital	12,405,395	9,719,147
Additional paid in capital for shares to be issued		278,600	[1]
Accumulated deficit during development stage	(9,548,746)	(7,185,402)
Total shareholders' equity	2,914,974	2,861,746
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 3,231,105	$ 3,108,504

[1] Represents 928,667 shares of common stock